138 related articles for article (PubMed ID: 20098471)
1. [Evolution of the darbepoetin alpha resistance index in patients on dialysis who change from weekly to fortnightly treatments in clinical practice].
López-Gómez JM; de Francisco AL; Montenegro J; de Santiago C; Vera M; Donapetry C; Villaverde M
Nefrologia; 2010; 30(1):64-72. PubMed ID: 20098471
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
3. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
Bajo MA; Pérez Fontán M; Remón C; Sánchez-Tomero JA; Lladós F; Selgas R
Nefrologia; 2009; 29(2):136-42. PubMed ID: 19396319
[TBL] [Abstract][Full Text] [Related]
4. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
5. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
6. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
7. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
[TBL] [Abstract][Full Text] [Related]
8. Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients.
Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M; Uchida K
Adv Perit Dial; 2011; 27():60-4. PubMed ID: 22073831
[TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
Bock HA; Hirt-Minkowski P; Brünisholz M; Keusch G; Rey S; von Albertini B;
Nephrol Dial Transplant; 2008 Jan; 23(1):301-8. PubMed ID: 17890745
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
[TBL] [Abstract][Full Text] [Related]
11. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
13. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
14. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
15. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
[TBL] [Abstract][Full Text] [Related]
16. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
[TBL] [Abstract][Full Text] [Related]
17. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
[TBL] [Abstract][Full Text] [Related]
18. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
Roger SD; Cooper B
Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
[TBL] [Abstract][Full Text] [Related]
19. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
20. An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months.
Rottembourg JB; Bridges I; Pronai W; Feriani M; McMahon LP; De Meester JM; Farouk M; Molemans B
Clin Nephrol; 2011 Mar; 75(3):242-50. PubMed ID: 21329635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
